Literature DB >> 33148082

Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma.

Pragya Rai1, Chan Shen2, Joanna Kolodney3, Kimberly M Kelly1, Virginia G Scott1, Usha Sambamoorthi1.   

Abstract

Background: The objective of this study is to assess the impact of immune checkpoint inhibitors (ICIs) and multimorbidity on healthcare expenditures among older patients with late-stage melanoma. Materials & methods: A retrospective longitudinal cohort study using Surveillance, Epidemiology and End Results linked with Medicare claims was conducted. Generalized linear mixed models were used to analyze adjusted relationships of ICI, multimorbidity and ICI-multimorbidity interaction on average healthcare expenditures.
Results: Patients who received ICI and those who had multimorbidity had significantly higher average total healthcare expenditures compared with ICI nonusers and no multimorbidity. In the fully adjusted model using ICI-multimorbidity interaction, no excess cost was added by multimorbidity.
Conclusion: Use of ICIs, regardless of multimorbidity, is associated with increased healthcare expenditures.

Entities:  

Keywords:  healthcare expenditures; immune checkpoint inhibitors; ipilimumab; medicare beneficiaries; melanoma; metastatic melanoma; multimorbidity; nivolumab; older patients; pembrolizumab

Mesh:

Substances:

Year:  2020        PMID: 33148082      PMCID: PMC8008205          DOI: 10.2217/imt-2020-0152

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  45 in total

1.  Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States.

Authors:  Vivek Verma; Waqar Haque; Taylor R Cushman; Chi Lin; Charles B Simone; Joe Y Chang; Shearwood McClelland; James W Welsh
Journal:  J Immunother       Date:  2019 Feb/Mar       Impact factor: 4.456

2.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

3.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Multimorbidity Trends in United States Adults, 1988-2014.

Authors:  Dana E King; Jun Xiang; Courtney S Pilkerton
Journal:  J Am Board Fam Med       Date:  2018 Jul-Aug       Impact factor: 2.657

5.  Cancer treatment cost in the United States: has the burden shifted over time?

Authors:  Florence K Tangka; Justin G Trogdon; Lisa C Richardson; David Howard; Susan A Sabatino; Eric A Finkelstein
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

6.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

7.  Medicare: a strategy for quality assurance.

Authors:  K N Lohr
Journal:  J Qual Assur       Date:  1991 Jan-Feb

8.  Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.

Authors:  Varsha Jain; Sriram Venigalla; Vishruth K Reddy; John N Lukens; Tara C Mitchell; Jacob E Shabason
Journal:  J Immunother       Date:  2020-01       Impact factor: 4.456

9.  Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.

Authors:  Sameer R Ghate; Raluca Ionescu-Ittu; Rebecca Burne; Briana Ndife; François Laliberté; Antonio Nakasato; Mei Sheng Duh
Journal:  Curr Med Res Opin       Date:  2018-08-05       Impact factor: 2.580

10.  The global burden of melanoma: results from the Global Burden of Disease Study 2015.

Authors:  C Karimkhani; A C Green; T Nijsten; M A Weinstock; R P Dellavalle; M Naghavi; C Fitzmaurice
Journal:  Br J Dermatol       Date:  2017-06-12       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.